TransPharma Medical has reported positive results from the Phase 1b trial of ViaDor-GLP1 agonist, which is being developed for the treatment of diabetes mellitus type II.
ViaDor-GLP1 application involves the use of TransPharma’s ViaDor drug delivery system featuring a handheld electronic device, which creates microscopic passageways through the outer layer of the skin for transdermal drug delivery from a patch.
The single-dose, four-way cross over study Phase 1b study was designed to evaluate the pharmacokinetic (PK) profile, safety and tolerability of ViaDor-GLP1 agonist in diabetic patients by using TransPharma’s extended release film patch.
The study involved 14 patients with type II diabetes, and compared once-daily application of three patch formulations versus twice daily subcutaneous injection of Exenatide (Byetta).
The study results demonstrated that ViaDor-GLP1 agonist was safe and well-tolerated with a preferable extended PK profile compared to Byetta.
Transdermal applications of ViaDor-GLP1 agonist lead to therapeutic blood levels for approximately 20 hours compared to 6 hours post injection of Exenatide.
The post postprandial glucose levels were consistent with ViaDor-GLP1 extended PK profiles.